ABCB1-Mediated Drug Efflux Drives Resistance to VpreB1-Targeted Antibody-Drug Conjugates in B-cell Lymphoblastic Leukemia
This study identifies ABCB1-mediated drug efflux as a key mechanism of resistance to VpreB1-targeted antibody-drug conjugates in B-cell acute lymphoblastic leukemia and demonstrates that this resistance can be overcome either by inhibiting ABCB1 or by utilizing non-ABCB1 substrate payloads.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Leukemia is a cancer of the blood and bone marrow, where the body produces too many immature white blood cells that crowd out healthy ones. For children and young adults, a specific type called B-cell acute lymphoblastic leukemia is the most common form. While modern treatments have made this disease highly curable for many, a stubborn group of patients still faces a grim outlook. These cases often involve cells that have learned to survive chemotherapy, a phenomenon known as drug resistance. To fight back, scientists have developed a new class of weapons called antibody-drug conjugates. Think of these as guided missiles: they consist of a targeting antibody that seeks out a specific protein on the surface of cancer cells, attached to a powerful poison. The antibody delivers the poison directly inside the cell, hoping to kill the cancer while leaving healthy tissue alone. However, even these sophisticated weapons can fail if the cancer cell has a way to eject the poison before it does its damage.
In a recent study, researchers at the University of Minnesota and collaborating institutions investigated why a promising new antibody-drug conjugate, designed to target a protein called VpreB1, failed to kill certain leukemia cells. VpreB1 is a marker found on the surface of early-stage B cells and many leukemia cells, making it an ideal target for this type of therapy. The team had previously shown that their VpreB1-targeted weapon worked well in many models, but they noticed that some cells, specifically those with a rare genetic change called TCF3::HLF, remained untouched. The scientists set out to understand how these resistant cells were surviving the attack. They first checked if the cancer cells had simply stopped showing the VpreB1 target or if they had stopped swallowing the antibody. Neither was true; the resistant cells still displayed the target and still took the antibody inside. The problem, they discovered, was what happened after the antibody entered the cell.
Inside the cell, the antibody releases its toxic payload, a substance called calicheamicin, which is designed to shred the cell's DNA. The researchers found that the resistant cells were equipped with a molecular pump, a protein known as ABCB1 or P-glycoprotein, that actively grabbed the released poison and threw it back out of the cell before it could cause harm. This pump is a well-known defense mechanism in cancer cells, often responsible for resistance to standard chemotherapy drugs. To prove this was the cause of the failure, the scientists treated the resistant cells with a drug called tariquidar, which acts as a blocker for this specific pump. When the pump was blocked, the poison could no longer escape. The resistant cells, which had previously shrugged off the treatment, suddenly became highly sensitive to the antibody-drug conjugate and died. The team confirmed this by engineering other leukemia cells to overproduce the pump; these new cells also became resistant, but only until the pump was blocked again.
The study also looked at whether this resistance was a universal problem for all antibody-drug conjugates or specific to the poison used. The researchers tested the resistant cells against other types of cancer-killing agents that are not recognized by the ABCB1 pump. They found that the cells remained vulnerable to these alternative poisons, such as exatecan and PNU-159682. This suggests that the resistance was not due to a general weakness in the cells' ability to die, but specifically because the pump was ejecting the calicheamicin payload. The team also examined bone marrow samples from twelve newly diagnosed patients with B-cell leukemia. They found that while all patients had the VpreB1 target, the levels of the ABCB1 pump varied widely, with some patients showing very high levels of the pump. This indicates that the resistance mechanism the team identified is not just a laboratory curiosity but likely exists in a subset of real patients.
The findings offer two clear paths forward for improving treatment. First, combining the antibody-drug conjugate with a pump-blocking drug like tariquidar could restore the treatment's power for patients whose cancer cells rely on this pump to survive. Second, and perhaps more broadly, the results suggest that designing future antibody-drug conjugates with poisons that the pump cannot recognize could bypass the problem entirely. The researchers noted that while blocking the pump has been tried before with standard chemotherapy, it may work better here because the antibody delivers the drug directly to the cancer cell, creating a more focused battle. By understanding exactly how the cancer cell defends itself, scientists can now choose better weapons or add the right shields to ensure the treatment succeeds, offering new hope for those with high-risk leukemia who have run out of options.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.